Fresenius Kabi Brasil Biopharma
Provider 
Founded —
Sells To —
Pricing Model —
Ownership —

Biopharma business unit of Fresenius Kabi Brasil offering biosimilar medicines in Brazil.
Fresenius Kabi Brasil Biopharma is the biopharmaceutical business unit of Fresenius Kabi in Brazil, offering biosimilar medicines for autoimmune diseases and oncology. The unit's pipeline focuses on immunology, oncology, hematology, and osteoporosis, with several molecules in development stages.
The unit operates within a fully integrated biopharmaceutical value chain covering research and development, production, supply, and commercialization, and complements its biosimilars offering with the KabiCare patient support program. Regulatory references on its portfolio page include ANVISA, the Brazilian health surveillance agency.
Bionovis

Bionovis — Biologic and Biosimilar Medicines
bionovis.com.br
Sandoz

Biosimilars
sandoz.com
Cristália

Biotechnology APIs & Biosimilars
cristalia.com.br
EMS

EMS — Hospital & Institutional Medicines
ems.com.br
Libbs Farmaceutica

Oncológicos
libbs.com.br
| Attribute | Fresenius Kabi Brasil Biopharma | Bionovis — Biologic and Biosimilar Medicines | Biosimilars | Biotechnology APIs & Biosimilars | EMS — Hospital & Institutional Medicines | Oncológicos | |
|---|---|---|---|---|---|---|---|
| Provider | |||||||
| Founded | — | 2012 | 1886 | 1972 | 1964 | 1958 | |
| Sells To | — | — | Healthcare Providers, Hospitals, Retail | Consumers, Hospitals | Consumers, Healthcare Providers, Hospitals | Consumers, Enterprise | |
| Pricing Model | — | — | B2B, Product Sales | Product Sales | B2B, Product Sales | Recurring, Software | |
| Ownership | — | — | Public | Private | Family-owned, Private | Private |
Provider 
Founded —
Sells To —
Pricing Model —
Ownership —
Provider 
Founded 2012
Sells To —
Pricing Model —
Ownership —
Provider 
Founded 1886
Sells To Healthcare Providers, Hospitals, Retail
Pricing Model B2B, Product Sales
Ownership Public
Provider 
Founded 1972
Sells To Consumers, Hospitals
Pricing Model Product Sales
Ownership Private
Provider 
Founded 1964
Sells To Consumers, Healthcare Providers, Hospitals
Pricing Model B2B, Product Sales
Ownership Family-owned, Private


Biocon's biosimilars portfolio spans trastuzumab, bevacizumab, pegfilgrastim, adalimumab, etanercept, and aflibercept products.
Samsung Bioepis's biosimilars portfolio includes etanercept, adalimumab, infliximab, trastuzumab, and aflibercept products.


Oncology category of Eurofarma's Brazilian product portfolio covering its cancer medicines.



Cristália's oncology-ingredients operation running Latin America's first high-potency oncology API plant, opened in 2019.
Amgen oncology therapy-area portfolio spanning small molecules, T-cell engagers, and monoclonal antibodies.
Biocon's biosimilars portfolio spans trastuzumab, bevacizumab, pegfilgrastim, adalimumab, etanercept, and aflibercept products.

Samsung Bioepis's biosimilars portfolio includes etanercept, adalimumab, infliximab, trastuzumab, and aflibercept products.
Oncology category of Eurofarma's Brazilian product portfolio covering its cancer medicines.

Truxima is a rituximab biosimilar medicine used in blood cancer and autoimmune care.

Cristália's oncology-ingredients operation running Latin America's first high-potency oncology API plant, opened in 2019.

Amgen oncology therapy-area portfolio spanning small molecules, T-cell engagers, and monoclonal antibodies.